obesity pill

Miriam E. Tucker November 06, 2025 ATLANTA — Eli Lilly’s investigational oral GLP-1 drug orforglipron produced significant weight loss, A1c reduction, and cardiovascular risk factor improvements in the company’s Phase 3 ATTAIN-2 trial of adults with both obesity and type 2 diabetes (T2D). Orforglipron is a once-daily small molecule (nonpeptide) that, unlike the current oral […]

by Madison Muller edited by Sadie Harley, reviewed by Andrew Zinin   Credit: Unsplash/CC0 Public Domain Eli Lilly & Co.’s experimental weight loss pill helped patients shed pounds without serious side effects in a clinical trial, burnishing the drug’s blockbuster potential in the company’s competition with Novo Nordisk A/S. The highest dose helped patients with type 2